BR112018008697A2 - method and kit for vaccination against an autoantigen, use of a kit, and vaccine for use in vaccination. - Google Patents
method and kit for vaccination against an autoantigen, use of a kit, and vaccine for use in vaccination.Info
- Publication number
- BR112018008697A2 BR112018008697A2 BR112018008697-5A BR112018008697A BR112018008697A2 BR 112018008697 A2 BR112018008697 A2 BR 112018008697A2 BR 112018008697 A BR112018008697 A BR 112018008697A BR 112018008697 A2 BR112018008697 A2 BR 112018008697A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- self
- dose
- administration
- immune response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15192794.4 | 2015-11-03 | ||
| EP15192794 | 2015-11-03 | ||
| PCT/EP2016/076372 WO2017076873A1 (en) | 2015-11-03 | 2016-11-02 | Method for vaccination against a self-antigen in a human patient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018008697A2 true BR112018008697A2 (en) | 2018-10-30 |
Family
ID=54396782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018008697-5A BR112018008697A2 (en) | 2015-11-03 | 2016-11-02 | method and kit for vaccination against an autoantigen, use of a kit, and vaccine for use in vaccination. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12290553B2 (enExample) |
| EP (1) | EP3370761A1 (enExample) |
| JP (2) | JP7378931B2 (enExample) |
| KR (1) | KR102857456B1 (enExample) |
| CN (1) | CN108472344A (enExample) |
| AU (1) | AU2016348610B2 (enExample) |
| BR (1) | BR112018008697A2 (enExample) |
| CA (1) | CA3003943A1 (enExample) |
| RU (1) | RU2734924C2 (enExample) |
| WO (1) | WO2017076873A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102857456B1 (ko) * | 2015-11-03 | 2025-09-08 | 에이씨 이뮨 에스에이 | 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법 |
| AR111760A1 (es) * | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| CN112533959A (zh) * | 2018-05-22 | 2021-03-19 | 阿尔伯塔大学理事会 | 用于基于结构的淀粉样蛋白疾病疫苗和抗原的无害的、结构化的支架 |
| CA3185563A1 (en) | 2020-08-04 | 2022-02-10 | Dorian WINTER | Immunogenic compounds |
| KR102527616B1 (ko) | 2021-03-18 | 2023-05-02 | 정성욱 | 항체 관련 정보를 제공하는 방법 및 디바이스 |
| MX2024009485A (es) | 2022-02-09 | 2024-08-14 | Ac Immune Sa | Vacunas terapeuticas anti-alfa-sinucleina. |
| WO2025172592A1 (en) | 2024-02-15 | 2025-08-21 | Ac Immune Sa | Alpha synuclein therapeutic vaccine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101077416A (zh) | 2002-10-23 | 2007-11-28 | 葛兰素史密丝克莱恩生物有限公司 | 抗疟疾的疫苗接种方法 |
| AT413945B (de) | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
| AT413946B (de) | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT508569A1 (de) | 2009-07-23 | 2011-02-15 | Affiris Ag | Pharmaceutical compound |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| ES2670576T3 (es) | 2009-09-03 | 2018-05-31 | Pfizer Vaccines Llc | Vacuna de PCSK9 |
| US9408907B2 (en) | 2009-12-15 | 2016-08-09 | Glaxosmithkline Biologicals Sa | Homogenous suspension of immunopotentiating compounds and uses thereof |
| EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP2666785A1 (en) | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
| EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
| DK3110439T3 (da) | 2014-02-28 | 2019-05-13 | Affiris Ag | Pcsk9-vacciner |
| KR102857456B1 (ko) | 2015-11-03 | 2025-09-08 | 에이씨 이뮨 에스에이 | 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법 |
-
2016
- 2016-11-02 KR KR1020187015512A patent/KR102857456B1/ko active Active
- 2016-11-02 CN CN201680064233.5A patent/CN108472344A/zh active Pending
- 2016-11-02 US US15/772,572 patent/US12290553B2/en active Active
- 2016-11-02 CA CA3003943A patent/CA3003943A1/en active Pending
- 2016-11-02 WO PCT/EP2016/076372 patent/WO2017076873A1/en not_active Ceased
- 2016-11-02 JP JP2018541534A patent/JP7378931B2/ja active Active
- 2016-11-02 AU AU2016348610A patent/AU2016348610B2/en active Active
- 2016-11-02 BR BR112018008697-5A patent/BR112018008697A2/en active Search and Examination
- 2016-11-02 RU RU2018120009A patent/RU2734924C2/ru active
- 2016-11-02 EP EP16793798.6A patent/EP3370761A1/en active Pending
-
2023
- 2023-08-24 JP JP2023136194A patent/JP7628333B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3003943A1 (en) | 2017-05-11 |
| US20190091306A1 (en) | 2019-03-28 |
| RU2734924C2 (ru) | 2020-10-26 |
| JP7628333B2 (ja) | 2025-02-10 |
| WO2017076873A1 (en) | 2017-05-11 |
| CN108472344A (zh) | 2018-08-31 |
| AU2016348610A1 (en) | 2018-05-10 |
| AU2016348610B2 (en) | 2023-08-31 |
| KR102857456B1 (ko) | 2025-09-08 |
| US12290553B2 (en) | 2025-05-06 |
| RU2018120009A3 (enExample) | 2020-04-23 |
| KR20180079406A (ko) | 2018-07-10 |
| RU2018120009A (ru) | 2019-12-04 |
| EP3370761A1 (en) | 2018-09-12 |
| JP7378931B2 (ja) | 2023-11-14 |
| JP2023175708A (ja) | 2023-12-12 |
| JP2018532782A (ja) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7628333B2 (ja) | ヒト患者における自己抗原に対するワクチン接種法 | |
| Wang et al. | UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease | |
| Ghochikyan et al. | Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch | |
| KR20110036809A (ko) | 파킨슨병과 관련된 증상을 치료하기 위한 화합물 | |
| JP5559789B2 (ja) | アルツハイマー病の処置のための免疫治療組成物 | |
| KR20120004994A (ko) | 치료적 이용 방법 | |
| US20150306194A1 (en) | Method for treating a synucleiopathy | |
| US20160008443A1 (en) | METHOD FOR TREATING A beta-AMYLOIDOSIS | |
| Maier et al. | Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT (R192G) | |
| TW201345927A (zh) | 組成物 | |
| JP2023536497A (ja) | 免疫原性化合物 | |
| Ding et al. | Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice | |
| EA048154B1 (ru) | Иммуногенные соединения | |
| AU2017221070A1 (en) | Amyloid conjugate and uses and methods thereof | |
| US20220218806A1 (en) | Peptides and conjugates for treatment of arthritis | |
| HK40087814A (zh) | 免疫原性化合物 | |
| TW201348264A (zh) | 組成物 | |
| NZ744411B2 (en) | Amyloid conjugate and uses and methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: AC IMMUNE SA (CH) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07C | Technical examination (opinion): republication [chapter 7.3 patent gazette] |
Free format text: REPUBLICACAO DO PARECER 7.1 NOTIFICADO NA RPI NO 2851. |